Astellas Pharma is a major supporter of the transplantation community. We have made significant advances in immunosuppression, improving outcomes in kidney, liver, and heart transplant recipients. Immunosuppressants are a class of drugs that suppress the immune response through various mechanisms. In organ transplantation, immunosuppressants are used to prevent the body from either recognizing or attacking the foreign organ via various immune responses.
With the goal of improving the quality of patient’s lives, Astellas works in partnership with the transplant community providing support to a number of causes.
Astellas is committed to continually striving to improve immunosuppression, and ultimately the lives of patients, by investing in the future of transplantation. The goal of our on-going research is to find compounds that will anticipate and address current and future unmet needs in the field of transplantation. We are dedicated to finding new ways to improve patient and graft survival through continued investment in our pipeline of potential future therapies, which includes investigation of all major signaling pathways.
Our mission is, to play a key role in the advancement of transplantation and begins with addressing today’s unmet needs, with a positive look to the future. Astellas Pharma is committed to making every endeavor to provide medicines that are recognized worldwide as improving outcomes for patients in every way possible following kidney, liver and heart transplantation.
